No. This new test is designed for use at CDC-supported public health laboratories at state and local levels, where it will supplement and streamline surveillance for flu and COVID-19. The use of this specialized test will be focused on public health surveillance efforts and will not replace any COVID-19 tests currently used in commercial laboratories, hospitals, clinics, and other healthcare settings.
CDC’s first viral test for SARS-CoV-2 (the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel (ER-34)) will still be available for qualified laboratories to order through the International Reagent Resource (IRR) external iconexternal icon. The new multiplex assay can also be ordered through the IRR. Check the IRR website for details.
For additional questions, please visit: Clinical Questions about COVID-19: Questions and Answers: Testing, Diagnosis, and Notification